Commons Sense

House of Commons · Written Ministerial Statement

Clinical trials

23 February 2026 · Department of Health and Social Care

Proposed by Wes Streeting Lab Ilford North

NHS

Summarised by AI from the official record, so it can contain mistakes.

View on Parliament.uk

At a glance

Key points

  • Wes Streeting updates Parliament on the pause of preliminary work for the PATHWAYS clinical trial regarding puberty suppressants for gender incongruence.
  • The MHRA has raised concerns about the trial.
  • Discussions to address these issues will begin this week.

Issue summary

Wes Streeting updates Parliament on the pause of preliminary work for the PATHWAYS clinical trial regarding puberty suppressants for gender incongruence.

Action requested

The MHRA has raised concerns about the trial, and discussions to address these issues will begin this week. The trial will not proceed until safety and clinical evidence support its continuation.

Key facts

  • The preliminary work for the PATHWAYS clinical trial has been paused.
  • The MHRA wrote a letter to King’s College London raising concerns about the trial.
  • Discussions between the MHRA and King’s College London will address these new concerns this week.
▸ Assessment & feedback
Summary accuracy